SOPHiA GENETICS has teamed with Synnovis to introduce the MSK-ACCESS® liquid biopsy test powered by SOPHiA DDM™ across the UK. This collaboration equips Synnovis’s pathology network with AI-driven ctDNA analysis for lung and breast cancer, enabling minimally invasive genomic profiling from a single blood draw.

Since the pilot began, Synnovis has processed approximately 400 liquid biopsy tests per month, accelerating personalized treatment plans by up to two weeks. Early cases include rapid ctDNA-informed therapy for advanced lung cancer and identification of new genetic variants in a long-term breast cancer patient, unlocking additional treatment options.

The partners project annual testing of 7,000 breast and lung cancer patients—about one third of England’s ctDNA screenings—under NHS England’s blood test-first program. Synnovis’s infrastructure and SOPHiA DDM™ scalability aim to accommodate growing demand and integrate future NHS cancer screening indications.

This partnership positions SOPHiA GENETICS to deepen its foothold in the UK’s genomic testing market and drive recurring AI-based diagnostics revenue. The model of distributed analysis hubs aligned with NHS data-security standards could serve as a blueprint for broader European precision oncology deployments.